Abstract Introduction Treatment advances in multiple myeloma (MM) have resulted in five-year survival improvements. However, gaps remain in access and adoption of standard of care (SOC) and novel therapies. As a result, variation in care persists. Project CoMMunity is a multi-center, local learning network to detect unmet needs, understand barriers impacting SOC treatment access, and address care gaps through innovative oncology partnerships and targeted interventions. Materials/Methods A multi-method approach was used to implement an integrated local learning network among academic and community oncology practices within New York City, NY and Winston-Salem, NC. A needs assessment and co-creation session to identify barriers and solutions was performed through community roundtables with diverse stakeholders. Electronic medical record data of patients with MM were compared across communities. Clinician-reported barriers and root causes limiting access and adherence to SOC treatments were solicited through 1:1 interviews. Results Among 12 clinicians and 4 social workers/patient advocates that participated in the roundtables, common barriers were health literacy/socioeconomic factors, limited community/academic clinical relationships, cultural/racial issues and low patient trust, complex patient priorities/medical conditions, and limited clinical trial exposure. Stakeholders indicated opportunities to support education and awareness, improve care continuity transitions among community and academic sites, and development of educational materials. Of 332 patients (NY 237; NC 95), quantitative analysis highlighted clinical variation in time from diagnosis to specialist visit (NY: 34 vs NC: 62 days), frontline therapy (1LOT) count (quadruplet, NY: 62.3% vs NC: 11.6%; triplet, NY: 34.3% vs NC: 79.0%) and stem cell transplantation incidence (NY: 30.8% vs NC: 50.5%). Time from diagnosis to 1LOT and proportion of patients referred to sub-specialists were consistent among sites. Overall, few patients (5.1%) received innovative therapies (eg, CAR-T, bispecific antibodies). Among 10 interviews, clinician-reported barriers and root causes limiting access to SOC treatment included patient characteristics, care barriers, referral/treatment protocols, and community engagement/support resources. Conclusion Local communities vary in needs, capacity, stakeholders, and existing healthcare infrastructure. Programs striving to improve access and adoption of SOC and novel therapies need to be multi-faceted and designed with local implementation in mind. A local learning network with regional participants provides a robust framework to efficiently transfer insights and clinical best practices while deploying local interventions that are responsive to needs of a diverse community. A one size fits all model will not succeed given unique setting and community needs. Citation Format: Cesar Rodriguez, John T. Mckay, Abdur Rahman Jabir, Alex Lieberman-Cribbin, Sean Paul Ormond, Kimberly Brunisholz, Kristi Cohn, Dianna S. Howard. Project CoMMunity: A local learning network deployed to address multiple myeloma care gaps in two communities [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 6358.

ABSTRACT:Interventions to maintain physical function during treatment may improve outcomes for older adults with acute myeloid leukemia (AML). We tested the feasibility of a randomized physical activity (PA) intervention among older adults (aged ≥60 years) receiving induction chemotherapy for newly diagnosed AML, and estimated the effect on physical function, quality of life (QOL), and symptoms. Intervention participants were offered PA sessions 5 days per week, tailored daily to symptoms during the induction hospitalization, along with weekly behavioral counseling sessions that continued monthly by phone for 6 months. The primary outcome was feasibility (recruitment, retention, and participation). The key secondary outcome of interest was the Short Physical Performance Battery (SPPB). SPPB score was assessed at baseline, weekly during hospitalization, and at 3 and 6 months. Among 96 eligible patients, 70 enrolled (mean age, 72.1 ± 6.3 years [range, 60-88]). Primary feasibility targets were met, with a recruitment rate of 72%, adherence of 74%, and average participation of 3 sessions per week. Among survivors, the retention rates were 96% and 95% at 3 (n = 51/53) and 6 (n = 42/44) months, respectively. In exploratory analyses, SPPB scores were maintained or improved in 38% of intervention participants vs 25% of controls at end of induction (n = 66; P = .21). There were no differences between groups in QOL or symptoms. A PA intervention with behavioral counseling during induction was feasible for older adults receiving intensive therapy for AML. This trial was registered at www.ClinicalTrials.gov as #NCT01519596.

e18548 Background: Relapsed disease after allogeneic stem cell transplant (alloHSCT) is the leading cause of post-transplant death. We retrospectively characterized the outcomes of patients with relapsed myeloid malignancy after first alloHSCT between 2020-2022 at the Atrium Health Levine Cancer Institute and Wake Forest Baptist Health Comprehensive Cancer Center. We report outcomes based on pretransplant factors, graft versus host disease(GVHD) and post relapse management. Kaplan Meier Estimates were used to estimate median survival time with 95% confidence intervals and Cox Proportional Hazards models to estimate hazard rates. Methods: Overall, 58 patients were included. The median time to relapse was 188 days. 26 patients had myeloablative conditioning and 32 had reduced intensity. GVHD prophylaxis was PtCy in 35 patients, ATG/Tac/Mtx in 21 and Tac/Mtx in 2. 45 patients died at the time of analysis, with a median survival of 227 days after relapse. Patients with relapse prior to day +180 had median survival of 158 days while those who relapsed after day 180 had median survival of 292 days. 28 patients developed graft versus host disease (GVHD) before or after relapse. 5 patients received post-transplant maintenance therapy prior to relapse. 3 received gilteritinib, 1 decitabine and GCSF, and 1 oral azacitidine. After relapse, 26 patients were treated with hypomethylating agent (HMA) + venetoclax, 18 patients received HMA alone, 4 patients were enrolled on clinical trials and 15 patients received 2 or more lines of salvage therapy. 20 patients received DLI, with an average of 1.5 infusions (1-3). 4 patients developed GVHD after DLI. 3 patients received a second alloHSCT. Multivariable Cox Proportional Hazards models were made for time to relapse (TtR) and time to death following relapse (TtD). Results: For TtR, maintenance therapy was associated with a 94% decreased hazard ratio (HR) for relapse p=(0.001)[CI 0.01-0.31]. High risk cytogenetics had a 2.22 increased HR for relapse (p=0.086)[0.89-5.54]. For TtD, patients with GVHD prior to relapse had a marginally significant 57% lower HR for death (p=0.074)[0.17-1.09], while patients who developed GVHD after relapse had a 2.74 greater risk of death (p=0.123)[0.76-9.82]. Those who received DLI had a 90% reduced risk of death (p<0.001)[0.03-0.26]. Patients with HMA+venetoclax had a 2.31 times greater risk of death than patients on HMA alone (p=0.077). Conclusions: Patients with myeloid malignancies who experienced relapse after alloHSCT had poor prognosis. Development of GVHD prior to relapse trended toward improved survival after relapse. In this cohort, maintenance chemotherapy prior increased time to relapse and DLI improved survival after relapse. The addition of venetoclax to HMA was associated with poorer survival compared to HMA alone. Patient characteristics. Gender M/F 33/25 Age <=65/>65 26/22 Disease AML 38 MDS 17 MDS/MPN 2 CMML 1 Donor Source MRD 7 MUD 34 Haplo 15 mMRD 1 mMUD 1

Purpose/objectivesHispanic and Latino (hereafter 'H/L') cancer survivors report higher rates of anxiety/depression and are less likely to receive psychosocial services than other survivors. We field-tested a culturally and linguistically adapted cognitive-behavioral therapy intervention with H/L post-treatment cancer survivors. Goals were to: (1) assess feasibility; (2) describe future efficacy outcomes; and (3) examine feedback for refinements.Design/research approachSingle-arm feasibility study.Sample/participantsH/L cancer survivors (N = 8).MethodsParticipants completed the 12-week CBT intervention, pre- and post-intervention measures, brief weekly feedback, and an in-depth interview. Recruitment, retention, and adherence, and changes in anxiety, depression, and fear of recurrence were summarized using descriptive statistics and 95% confidence intervals.FindingsOf 44 H/L survivors approached, 18 agreed to screening, and 9 met criteria; 8 enrolled over 7.4 months. Although we did not perform formal hypothesis testing, we observed clinically meaningful decreases in anxiety and depression. All who completed the intervention (n = 7) recommended the intervention.ConclusionWhile recruitment was challenging, participants reported robust decreases in depression and/or anxiety and high intervention satisfaction.Implications for psychosocial providers or policyFuture work should explore ways to decrease stigma and enhance recruitment to fully evaluate the adapted intervention among H/L survivors.

Post-transplant cyclophosphamide has gained widespread use as GVHD prophylaxis due to superior outcomes in overall survival as well as decreased rate of acute and chronic GVHD as compared to ATG and methotrexate-based GVHD prophylaxis. To avoid the risk of hemorrhagic cystitis associated with cyclophosphamide, various hyperhydration protocols have been used to dilute acrolein, the toxic metabolite excreted in the urine. These protocols vary from 3-6L of IV hydration per day +/- diuresis and may carry risk of volume overload and renal .Our standard hydration protocol is 250 mL NS/hour beginning 24 hours before the first dose of PTCy on Day+3 and ending 24 hours after second dose on Day +4. Furosemide 20 mg IV q8h PRN is given for a +1L fluid balance. We conducted a chart review of 37 patients receiving PTCy as GVHD prophylaxis between 2020 and 2022 at our institution to query renal failure, hypoxia, pulmonary edema and AKI as complications, also taking into account other potential causative factors such as exposure to CT contrast, supratherapeutic FK506 trough, and vancomycin exposure. AKI was defined using KDIGO criteria for increase in creatinine of 0.3 or greater over 48 hours or increase of 1.5x over baseline (defined as creatinine on day of admission) with insult occurring within prior 7 days.Out of 37 patients, patients had AML, MDS, HL, MF, MDS/MPN and aplastic anemia. PBSC were graft source for all patients. 3 Patients required ICU transfer: 1 for pulmonary edema and fluid overload, 2 for septic shock. 3 patients developed fluid overload/heart failure exacerbation. 29% (n=11) of patients developed AKI during transplant hospitalization. Of these 11 patients, only 2 did not receive vancomycin, IV contrast or have supratherapeutic FK506 level. One patient remained dialysis dependent after transplant.These data show that there are multiple possible renal insults during initial hospitalization for allogeneic stem cell transplant. Fluid overload, as seen by marked weight increase and/or elevated BNP and renal injury were observed in patients receiving PTCy and associated hyperhydration. This data may be used to modify our hyperhydration protocol by decreasing hydration in selected patients who may be at more risk of fluid overload from aggressive hyperhydration and to identify patients early on who may be at risk of AKI.

Allogeneic hematopoietic cell transplantation (HCT) improves outcomes for patients with AML harboring an internal tandem duplication mutation of

Adolescent and young adult cancer survivors (AYAs) experience clinically significant distress and have limited access to supportive care services. Interventions to enhance psychological well-being have improved positive affect and reduced depression in clinical and healthy populations and have not been routinely tested in AYA survivors. We are optimizing a web-based positive skills intervention for AYA cancer survivors called Enhancing Management of Psychological Outcomes With Emotion Regulation (EMPOWER) by: (1) determining which intervention components have the strongest effects on well-being and (2) identifying demographic and individual difference variables that mediate and moderate EMPOWER's efficacy. EMPOWER is a five-session online intervention that teaches behavioral and cognitive skills for increasing psychological well-being. Guided by the Multiphase Optimization Strategy (MOST), we assign two levels (yes, no) to each of five intervention components (positive events, capitalizing, & gratitude; mindfulness; positive reappraisal; personal strengths & goal-setting; acts of kindness), allowing us to evaluate the effects of individual and combined intervention components on positive affect in a full factorial design. Post-treatment AYA cancer survivors (N = 352) are recruited from participating NCI-designated comprehensive cancer centers and randomized to one of 32 experimental conditions. Our primary outcome is positive affect; potential mediating and moderating variables include coping self-efficacy and emotional support, respectively. Upon trial completion, we will have an optimized, digital health intervention to enhance psychological well-being among AYA cancer survivors. EMPOWER will be scalable and primed for a large, multi-site trial among AYAs who would otherwise not have access to supportive care interventions to manage distress and enhance well-being.

Purpose/Objectives: The purpose of this study was to transcreate a cognitive-behavioral therapy (CBT) intervention to address depression and anxiety among Hispanic cancer survivors. Design/Research Approach: Stakeholders reviewed the CBT workbook for language, content, and cultural relevance. We designed semi-structured interview guides to elicit intervention feedback. Sample/Participants: Stakeholder participants were Hispanic cancer survivors (n = 4), bilingual mental health providers (n = 2), and oncology professionals (n = 4). Methods: Transcreation was conducted by initial translation of the workbook followed by incorporation of stakeholder feedback. A bilingual (Spanish and English) interviewer conducted stakeholder interviews. The study team discussed themes/suggestions before refining the workbook. Findings: Stakeholders reported enthusiasm for the intervention. We gathered significant feedback regarding wording, images, and resources for the workbook. Conclusion: Development of culturally appropriate mental health resources for Hispanic cancer survivors is critical. Implications for Psychosocial Providers or Policy: By broadening research on psychosocial care to the Hispanic population, we increase the reach of evidence-based psychological care. Future research should fully evaluate the adapted CBT intervention among Hispanic survivors.

Purpose: Financial hardship as a result of cancer treatment can have a significant and lasting negative impact on adolescents and young adults (AYAs) and their families. To address a lack of developmentally informed and psychometrically sound measures of financial hardship for AYAs and their caregivers, we used rigorous measurement development methods recommended by the National Institutes of Health's Patient-Reported Outcomes Measurement Information System® (PROMIS®) to determine comprehensibility and relevance of measure content. Methods: Our multi-step approach involved item identification, refinement, and generation; translatability and reading level review; and cognitive interviews. A purposive sample of 25 AYAs and 10 caregivers participated, ensuring representation across age, education, gender, race/ethnicity, and cancer type. Results: Fifty patient-reported and caregiver-reported items were developed across material, psychosocial, and behavioral subdomains of financial hardship. Translatability and reading level reviews resulted in 22 patient-reported and 25 caregiver-reported items being rewritten. Eighty-eight percent of patients and all caregivers described the items as easy to answer. Younger AYAs (15 to 25 years of age) were more likely to say the items were less relevant for them. Forty-six patient-reported and 48 caregiver-reported items were recommended for further testing. Conclusion: This study is the first to use in-depth qualitative methods to center AYA patient and caregiver experiences in the creation of new measures of financial hardship. Data support the comprehensibility and content validity of these preliminary item banks. Future large-scale, quantitative testing will lead to additional refinements and support the use of short forms and computer-adaptive testing for a diverse sample of AYAs and their caregivers.

Introduction: CAR T-cell therapy has made a significant impact in the treatment of relapsed and refractory (R/R) DLBCL. However, there are significant barriers to timely administration of CAR T. Vein-to-vein time (time between leukapheresis and CAR T infusion) is an important barrier reported by clinical trials. In the real world, administration of CAR T may be further delayed due to financial clearance or single case agreement (SCA), shortage of leukapheresis slots, disease progression and death, among others. The time between CAR T referral and infusion (brain-to-vein) in the real-world is unknown. Understanding the barriers to timely administration of CAR T is crucial to expanding the access to CAR T for patients with R/R DLBCL. Methods: Adult patients (pts) with R/R DLBCL who underwent consultation for CAR T at our center from 2018 to 2022 were included in the study. The following information was collected from each subject and analyzed with descriptive statistics: referral type (internal/external), insurance type (private/government), private insurance subtype (SCA/non-SCA), and CAR T product (liso-cel/axi-cel/clinical trial/non-conforming product). For continuous variables, we reported the median and range, while categorical variables were reported as frequencies and percentages. The brain-to-vein time was classified as high (70-130 d), medium (45-70 d), and low (27-45 d). The effects of variables on brain-to-vein time were analyzed by Fisher's exact test for categorical variables, and Wilcoxon rank-sum test for continuous variables. Survival analyses were performed using the Kaplan-Meier and Cox Proportional Hazard model. Results: The study included 78 consecutive pts who were referred for consideration of CAR T for DLBCL. Thirteen (16.6%) pts did not receive CAR T therapy due to disease progression and death (n=5), lack of social support or caregiver (n=4), lack of financial clearance (n=2), and complete response to bridging therapy (n=2). Sixty-five (83.3%) pts received CAR T therapy. Median age was 61 y (27-83), 72% were male, and 18.4% belonged to racial or ethnic minority groups. The median time (range) from consultation to financial clearance, leukapheresis, and CAR T infusion were 15 (-50, 89), 30 (3, 91) and 61 d (27, 130), respectively. For some pts financial clearance was obtained prior to consultation. The median vein-to-vein time was 31 d (16, 76). There was no difference in brain-to-vein time (p=0.66) for external and internal referrals. Although pts with private insurance took longer to obtain financial clearance compared to pts with government insurance (median, 20 vs 9 d, p=0.01) (Table 1), there was no significant difference in the brain-to-vein time between the 2 groups (p=0.24). 20% of pts with private insurance needed SCA. Compared to those who did not need SCA, pts who needed SCA had a significant delay in time from consultation to financial clearance (median, 30 vs 19 d, p=0.01) and CAR T infusion (median 79 vs 55 d, p<0.001) (Table 2). Brain-to-vein time was significantly different among different products, with clinical trial the shortest (47 d, n= 9), non-conforming products the longest (99 d, n=5), and axi-cel (57 d, n=40), liso-cel (75 d, n=11) in between (p<0.001; Table 3). Of the 5 pts who received non-conforming products, 4 were intended for liso-cel and 1 for axi-cel. Brain-to-vein time did not significantly impact the progression-free survival [hazard ratio (HR)=0.988, 95% confidence interval (CI) = 0.973-1.003, p=0.11) or overall survival (HR=0.990, 95%CI=0.972-1.009, p=0.30) (Table 4). There was concordance when the time from consultation to CAR T therapy was used as a continuous variable and when it was separated into low, medium, and high quartiles and tested as categorical variables (Tables 2-4). Conclusion: We have identified multiple factors that prolonged brain-to-vein time for CAR T-cell therapy in the real-world. Pts whose insurance required SCA or who received non-conforming products had significant delay in receiving CAR T. Although delay in receiving CAR T therapy did not impact survival at our institution, several patients who could have benefited from CAR T did not receive it due to disease progression/death (6.4%) or lack of financial clearance (2.6%). Rapid financial clearance and eliminating the need for SCA could abbreviate the brain-to-vein time and expand access to patients with rapidly progressive DLBCL.

Immune effector cell (IEC) therapy represents a transformative advancement in oncology, leveraging the immune system to combat various malignancies. This article outlines a comprehensive framework for establishing and maintaining quality standards in IEC therapy amidst rapid scientific and clinical advancements. We emphasize the integration of structured process measures, robust quality assurance, and meticulous outcome evaluation to ensure treatment efficacy and safety. Key components include multidisciplinary expertise, stringent accreditation protocols, and advanced data management systems, which facilitate standardized reporting and continual innovation. The collaborative effort among stakeholders-ranging from patients and healthcare providers to regulatory bodies-is crucial in delivering high-quality IEC therapies. This framework aims to enhance patient outcomes and cement the role of IEC therapy as a cornerstone of modern oncology, promoting continuous improvement and adherence to high standards across the therapeutic spectrum.

Acute lymphoblastic leukemia (ALL) is an aggressive bone marrow cancer with disparate outcomes. Data on patient outcomes in real world settings outside of clinical trials is limited. The current study reports on outcomes for 137 ALL patients who received an adult induction and consolidation regimen derived from the CALGB 10102 trial modified without alemtuzumab. Of the 137 patients, 32 were < 40 years old, 52 were between 40 and 59, and 53 were ≥ 60 years old. Overall, 109 (79.6

Allogeneic hematopoietic cell transplantation (HCT) is increasingly offered to older adults with hematologic malignancies, even though nonrelapse mortality remains a major concern in older patients owing to more comorbidities and greater frailty compared with their younger counterparts. The importance of patient fitness, a well-matched donor, and disease control to the success of allogeneic HCT have been well documented; however, these factors fail to account for the impact of the complex transplantation ecosystem (TE) that older adult HCT candidates must navigate. We propose a definition of the TE modeled after the social determinants of health. Furthermore, we outline a research agenda aimed at increasing understanding of the roles of individual social determinants of transplantation health in the larger ecosystem and how they may benefit or harm older adult HCT candidates. Herein we define the TE and its individual tenets, the social determinants of transplantation health. We review the available literature while incorporating the expertise of the membership of the American Society for Transplantation and Cellular Therapy (ASTCT) Special Interest Group for Aging. The membership of the ASTCT Special Interest Group for Aging identify knowledge gaps and strategies to address them for each of the described social determinants of transplantation health. The ecosystem is an essential but underappreciated pillar for transplant access and success. We put forth this novel research agenda seeking to gain a better understanding of the complexity of HCT in older adults and develop strategies to improve access to HCT, survival, and quality of life.

Figure S1. Dose escalation schema. Figure S2. Acetyl-CoA synthetase is expressed in OCI-AML3 and MFL2 cells. Figure S3 Acetate and methyl-succinate rescue of CPI-613 cytotoxicity. Figure S4. Treatment schema. Figure S5. Efficacy of HiDAC, mitoxantrone and CPI-613. Figure S6. Baseline bone marrow mononuclear cell gene expression profiles of responders (n=10) versus nonresponders (n=7). Figure S7. SOD2 expression levels are higher in non-responders Figure S8. SOD2 confers resistance to CPI-613. Figure S9. Mutational analysis from RNA sequence data of baseline marrow samples. Supplemental Table 1. Dose and Response by Patient Supplementary Table 2. Gene ontology enrichment analysis of genes overexpressed in responding patients

Devimistat is a TCA cycle inhibitor. A previously completed phase I study of devimistat in combination with cytarabine and mitoxantrone in patients with relapsed or refractory AML showed promising response rates. Here we report the results of a single arm phase II study (NCT02484391). The primary outcome of feasibility of maintenance devimistat following induction and consolidation with devimistat in combination with high dose cytarabine and mitoxantrone was not met, as maintenance devimistat was only administered in 2 of 21 responders. The secondary outcomes of response (CR + CRi) and median survival were 44% (21/48) and 5.9 months respectively. There were no unexpected toxicities observed. An unplanned, post-hoc analysis of the phase I and II datasets suggests a trend of a dose response in older but not younger patients. RNA sequencing data from patient samples reveals an age-related decline in mitochondrial gene sets. Devimistat impairs ATP synthesis and we find a correlation between mitochondrial membrane potential and sensitivity to chemotherapy. Devimistat also induces mitochondrial reactive oxygen species and turnover consistent with mitophagy. We find that pharmacological or genetic inhibition of mitochondrial fission or autophagy sensitizes cells to devimistat. These findings suggest that an age related decline in mitochondrial quality and autophagy may be associated with response to devimistat however this needs to be confirmed in larger cohorts with proper trial design.

OBJECTIVE:Adolescent and young adult (AYA) cancer survivors are vulnerable to cancer-related financial burden, which is likely shared by their caregivers. This study aims to enhance an existing conceptual model of financial burden by conducting concept elicitation interviews with caregivers to generate knowledge that can be translated to inform instrumental and psychosocial support in cancer care. METHODS:Qualitative concept elicitation interviews were conducted with 24 caregivers of AYA cancer survivors (caregivers of adolescents, n = 12; caregivers of emerging adults, n = 12) recruited from four sites. Constant comparative methods were used to identify themes, and results were interpreted and organized into domains of the conceptual model. We also explored COVID-19 related financial impacts among a subset (n = 12) of caregivers. RESULTS:Seven themes emerged, which varied by age group and strengthened the conceptualization of the model. Themes centered on: (1) direct and indirect costs of cancer; (2) impact of socioeconomic status on financial burden; (3) caregiver desire to shield AYAs from distress due to financial burden; (4) strategies to manage cancer-related costs; (5) worries about AYAs' financial future; (6) seeking and receiving financial support; and (7) navigating the healthcare system. Findings also revealed that COVID-19 exacerbates financial burden for some caregivers. CONCLUSIONS:Building upon our prior work, we have adapted the conceptual model of financial burden to reflect perspectives of AYAs, oncology providers, and now, caregivers. An important next step is to develop a reliable and valid self-report measure of financial burden among caregivers of AYA cancer survivors.

The cost of cancer care is rising and represents a stressor that has significant and lasting effects on quality of life for many patients and caregivers. Adolescents and young adults (AYAs) with cancer are particularly vulnerable. Financial burden measures exist but have varying evidence for their validity and reliability. The goal of this systematic review is to summarize and evaluate measures of financial burden in cancer and describe their potential utility among AYAs and their caregivers. To this end, the authors searched PubMed, Embase, the Cochrane Library, CINAHL, and PsycINFO for concepts involving financial burden, cancer, and self‐reported questionnaires and limited the results to the English language. They discarded meeting abstracts, editorials, letters, and case reports. The authors used standard screening and evaluation procedures for selecting and coding studies, including consensus‐based standards for documenting measurement properties and study quality. In all, they screened 7250 abstracts and 720 full‐text articles to identify relevant articles on financial burden. Eighty‐six articles met the inclusion criteria. Data extraction revealed 64 unique measures for assessing financial burden across material, psychosocial, or behavioral domains. One measure was developed specifically for AYAs, and none were developed for their caregivers. The psychometric evidence and study qualities revealed mixed evidence of methodological rigor. In conclusion, several measures assess the financial burden of cancer. Measures were primarily designed and evaluated in adult patient populations with little focus on AYAs or caregivers despite their increased risk of financial burden. These findings highlight opportunities to adapt and test existing measures of financial burden for AYAs and their caregivers.